NKGN (NKGen Biotech) Total Stockholders Equity : $-47.05 Mil (As of Sep. 2024)

View and export this data going back to 2023. Start your Free Trial

What is NKGen Biotech Total Stockholders Equity?

NKGen Biotech's Total Stockholders Equity for the quarter that ended in Sep. 2024 was $-47.05 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. NKGen Biotech's Book Value per Share for the quarter that ended in Sep. 2024 was $-1.32. The ratio of a company's debt over equity can be used to measure how leveraged this company is. NKGen Biotech's Debt-to-Equity for the quarter that ended in Sep. 2024 was -0.65.

NKGen Biotech Total Stockholders Equity Historical Data

The historical data trend for NKGen Biotech's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NKGen Biotech Total Stockholders Equity Chart

NKGen Biotech Annual Data

Trend

Dec21

Dec22

Dec23

Total Stockholders Equity

-38.05

1.56

-58.69

NKGen Biotech Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Stockholders Equity	Get a 7-Day Free Trial					-40.64	-58.69	-55.06	-69.72	-47.05

NKGen Biotech (OTCPK:NKGN) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

NKGen Biotech's Book Value per Share for the quarter that ended in Sep. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(-47.05	-	0)	/	35.716
	=	-1.32

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

NKGen Biotech's Debt-to-Equity for the quarter that ended in Sep. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(19.854	+	10.886)	/	-47.05
	=	-0.65

NKGen Biotech Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of NKGen Biotech's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

NKGen Biotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NKGen Biotech Inc (OTCPK:NKGN) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

3001 Daimler Street, Santa Ana, CA, USA, 92705

Website

https://www.nkgenbiotech.com

NKGen Biotech Inc is a biotechnology company developing cell therapies for neurodegenerative and oncological diseases based on activated NK cells. NK cells are part of the human innate immune response system that can selectively identify and destroy abnormal or diseased cells. Its product candidates are based on a proprietary manufacturing and cryopreservation process that produces SuperNKTM (SNK) cells that have shown increased activity as compared to the starting population of NK cells, based on the results of in vitro experiments performed by NKMAX, as defined by parameters such as cytotoxicity, cytokine production and activating receptor expression. SNK cells can be produced in large quantities and cryopreserved while maintaining high levels of cytotoxicity.